LXEO
Lexeo Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.76
+4.55%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +24.1%
- EBIT
- +22.9%
- EPS
- +64.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +66.3%
- EPS
- -19.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- -1.5%
- EBIT
- -3.3%
- Net income
- -1.7%
- EPS
- +39.8%
- Free cash flow
- -21.2%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026